Viatris (HAM:VIA) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


HAM:VIA Viatris Inc HAM:VIA
58 GF Score
Price €14.26
GF Value €9.77
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Viatris Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Viatris's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

HAM:VIA vs NBIX, UTHR, ELAN: Margin of Safety % (DCF FCF Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viatris Margin of Safety % (DCF FCF Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Viatris's Margin of Safety % (DCF FCF Based) falls into.


HAM:VIA
58GF Score
Viatris Inc HAM:VIA
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Viatris (HAM:VIA) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of €14.26 is trading 45.9% above its estimated GF Value™ of €9.77. GuruFocus considers Viatris to be Significantly Overvalued.

Key valuation signals for HAM:VIA:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €9.77 vs. price of €14.26 (45.9% above fair value)
  • GF Score™: 58/100 with 7 warning signs

No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
58GF Score

Get the complete analysis for HAM:VIA

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.26
Price
€9.77
GF Value